Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study

In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide–based regimens in virologically suppressed individuals with HIV-1. Antiretroviral agents have been associated with weight gain and metabolic complications. SETTING: One hundred th...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wyk, Jean, Ait-Khaled, Mounir, Santos, Jesus, Scholten, Stefan, Wohlfeiler, Michael, Ajana, Faïza, Jones, Bryn, Nascimento, Maria-Claudia, Tenorio, Allan R., Smith, Don E., Wright, Jonathan, Wynne, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126488/
https://www.ncbi.nlm.nih.gov/pubmed/33587500
http://dx.doi.org/10.1097/QAI.0000000000002655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126488/
https://www.ncbi.nlm.nih.gov/pubmed/33587500
http://dx.doi.org/10.1097/QAI.0000000000002655

Ejemplares similares